Printer Friendly
The Free Library
18,914,768 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Medstone Receives Recommendation For Approval From FDA Panel For Treatment of Gallstones.


ALISO VIEJO, Calif.--(BW HealthWire)--May 1, 1998--Medstone International Inc. (Nasdaq: MEDS meds A popular term for physician-prescribed medications ) has been notified that the FDA's Gastroenterology and Urology Device Advisory Panel has recommended conditional approval of Medstone's submission to treat gallstones Gallstones Definition

A gallstone is a solid crystal deposit that forms in the gallbladder, which is a pear-shaped organ that stores bile salts until they are needed to help digest fatty foods.
 using the company's lithotripter lithotripter /litho·trip·ter/ (lith´o-trip?ter) an instrument for crushing calculi in lithotripsy.

lith·o·trip·ter
n.
, in combination with Actigall, a drug used to dissolve gallstones. The condition to approval is that Medstone performs a post-approval study.

"The recommendation for approval is another step along the approval trail. This step was taken after many years of hard work by a group of talented people. We believe this combined therapy will be a valuable tool for the physicians in treating certain patients with gallstones," said David V. Radlinski, chairman and chief executive officer.

Medstone, as the only vertically integrated extracorporeal shockwave therapy Extracorporeal Shock Wave Therapy or ESWT is a method of treatment of kidney stones (Extracorporeal Shockwave Lithotripsy), shoulder tendinitis, and other conditions by application of high-intensity ultrasonic acoustic radiation.  ("ESWT ESWT Extracorporeal shock wave lithotripsy, see there ") company, is focused on providing cost effective lithotripsy for treatment of various diseases.

CONTACT: Medstone International Inc.

David V. Radlinski, 714/448-7700, Ext. 235
COPYRIGHT 1998 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1998, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:May 1, 1998
Words:148
Previous Article:Hospitality Worldwide Services First Quarter Net Income Triples On 126% Revenue Gain.
Next Article:Cornerstone Properties is in Merger Talks With William Wilson & Associates, Reports the San Francisco Business Times.
Topics:



Related Articles
Lithotriptor therapy coming of age.
Panel backs DDI despite uncertainties. (Food and Drug Administration panel recommends approving AIDS drug didanosine)
AIDS drug finds a booster in FDA panel. (dideoxycytidine) (Brief Article)
Medstone's Submission For Gallstones Is Filed and Panel Date Set.
Tamoxifen clears hurdle to preventive use.(breast cancer drug)
FDA Gives Salvage Therapy Testing a Push Forward.
MINIMED OPENS STRONG THEN FADES FOR MILD GAIN.(Business)(Statistical Data Included)
MINIMED TEST DEVICE GAINS OK FROM PANEL.(BUSINESS)
Risk factors for gallstone disease in a hospital-based study.
Amgen data debate.(HEALTH CARE & BIOTECH)

Terms of use | Copyright © 2010 Farlex, Inc. | Feedback | For webmasters | Submit articles